Entheon Biomedical Corp.: Entheon Biomedical Announces Expanded Psychedelics Genetic Test Panel & New Clinical Research Platform

Improved Genetic Screening Platform to Strengthen Entheon's Psychedelic-Assisted Protocols
Vancouver, British Columbia--(Newsfile Corp. - March 29, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB:

Related Keywords

United States ,Canada ,United Kingdom ,Vancouver ,British Columbia ,British ,Canadian ,Brian Jahns ,Timothy Ko ,Joseph Cullen ,Halugen Life Sciences Inc ,European Union ,Entheon Biomedical Corp ,Financing Issue Price Of The Company ,British Columbia Newsfile Corp ,Canadian Securities Exchange ,Improved Genetic Screening Platform ,Strengthen Entheon ,Halugen Life Sciences ,Psychedelics Genetic Test Kit ,Psychedelics Genetic Test ,Chief Executive Officer ,Loan Agreements ,Future Financing ,Each Warrant ,Financing Issue Price ,Investor Relations ,Chief Business ,Entheon ,Iomedical ,Orp ,Nnounces ,Xpanded ,Psychedelics ,Enetic ,Pest ,Panel ,Linical ,Research ,Platform ,